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OBJECTIVES The goal of our study was to determine the incidence and predictors of atrial flutter in the
general population.
BACKGROUND Although atrial flutter can now be cured, there are no reports on its epidemiology in
unselected patients.
METHODS The Marshfield Epidemiological Study Area (MESA), a database that captures nearly all
medical care among its 58,820 residents was used to ascertain all new cases of atrial flutter
diagnosed from July 1, 1991 to June 30, 1995. To identify predisposing risk factors, we
employed an age- and gender-matched case-control study design using eight additional
variables.
RESULTS A total of 181 new cases of atrial flutter were diagnosed for an overall incidence of 88/100,000
person-years. Incidence rates ranged from 5/100,000 in those ,50 years old to 587/100,000
in subjects older than 80. Atrial flutter was 2.5 times more common in men (p , 0.001). The
risk of developing atrial flutter increased 3.5 times (p , 0.001) in subjects with heart failure
and 1.9 times (p , 0.001) for subjects with chronic obstructive pulmonary disease. Among
those with atrial flutter 16% were attributable to heart failure and 12% to chronic obstructive
lung disease. Three subjects (1.7%) without identifiable predisposing risks were labeled as
having “lone atrial flutter.”
CONCLUSIONS This study, the first population-based investigation of atrial flutter, suggests this curable
condition is much more common than previously appreciated. If our findings were applicable
to the entire U.S. population, we estimate 200,000 new cases of atrial flutter in this country
annually. At highest risk of developing atrial flutter are men, the elderly and individuals with
preexisting heart failure or chronic obstructive lung disease. (J Am Coll Cardiol 2000;36:
2242–6) © 2000 by the American College of Cardiology
Atrial flutter is a condition in which, as has recently been
shown, the contraction wave follows a circular and never ending
path in the auricle, the circuits being completed at a rate of from
240 to 350 per minute in different subjects.
Sir Thomas Lewis, 1920 (1)
Recent technological advances have improved our under-
standing of the electrophysiologic substrate responsible for
atrial flutter (2–8). Clinical application of this knowledge
has made catheter-based radiofrequency ablation (RFA) a
safe and effective therapeutic procedure (9–19).
Despite these technical developments, little is known
about the epidemiology of atrial flutter in the general
population (20). Our objectives were to determine its
incidence and predisposing conditions.
METHODS
Marshfield Epidemiologic Study Area (MESA). Our in-
stitutional review board approved the study. Population-
based epidemiologic research is feasible in central Wiscon-
sin because the Marshfield Clinic and St. Joseph’s Hospital
provide almost all health care in this region. These institu-
tions share a system of medical records including informa-
tion on nearly all inpatient and outpatient encounters. The
MESA has been established to conduct epidemiologic
studies and population-based health research in a ZIP
code-defined region that includes Marshfield and surround-
ing communities. Since most MESA residents (over 70%)
have at least one health-related encounter every year and the
health care status and the denominator of the population are
updated daily, accurate longitudinal follow-up of individuals
is possible. We have shown that over 95% of 58,820 area
residents and virtually all health events are captured in the
MESA database, including 99% of deaths, 94% of hospital
discharges and 92% of medical outpatient visits (21).
Electrocardiographic definitions. Only patients with elec-
trocardiographic (ECG) evidence of their first episode of
atrial flutter (duration $5 s) were enrolled. Entry criteria
required: a) standard 12-lead ECG or tracings obtained at
the time of exercise stress test or b) ECG monitor or Holter
strip recordings.
Atrial flutter was considered to be present if there were
visible and highly regular “F” waves at a rate #350 beats/
min. Highly regular “F” waves were defined as those in
which the cycle to cycle atrial variability was #10 ms. Atrial
flutter rate had to be greater than 190 beats/min among
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patients receiving classes IA, IC or class III antiarrhythmic
(AA) agents. In all others, the lowest acceptable atrial rate
was 240 beats/min.
Patient selection criteria. To identify potential incident
cases of atrial flutter, we used Marshfield Clinic’s diagnostic
database. Since 1979 this database has used the Interna-
tional Classification of Diseases (ICD) to track all diagnos-
tic codes. To ensure complete ascertainment of all cases
occurring from July 1, 1991 through June 30, 1995, we
employed eight ICD, 9th revision, Clinical Modification
(ICD-9-CM) codes in our initial screening. In addition to
ICD 427.32 (atrial flutter), we used seven additional codes
including 410 (acute myocardial infarction), 426.7 (Wolff-
Parkinson-White syndrome), 427.0 (paroxysmal supraven-
tricular tachycardia [PSVT]), 427.2 (paroxysmal tachycardia
unspecified), 427.31 (atrial fibrillation), 427.81 (sinoatrial
node dysfunction), 427.89 (other rhythm disorder, ectopic,
nodal and wandering atrial pacemaker) and 427.9 (cardiac
dysrhythmia, unspecified).
Since all patients diagnosed with these conditions were
assessed for inclusion, approximately 2,000 potential inci-
dent cases of atrial flutter were screened. Final case inclusion
required ECG confirmation atrial flutter by cardiac electro-
physiologists. All eligible cases were enrolled. During
220,000 person-years of observation, approximately
29,000 ECG and rhythm strips, 1,100 Holter monitors and
500 ambulatory event recordings were obtained from
MESA residents.
Selection of controls. Since age and gender are important
predictors of disease and survival, each incident case was
matched with a population-based control of the same age
and sex. Controls were chosen randomly among MESA
residents without previously documented atrial arrhythmias.
Indications or complaints prompting health encounters
among controls at the time of study entry were: a) a
prescheduled office visit in 61% (including 36% with eye or
dental appointments or cutaneous or musculoskeletal con-
cerns), b) scheduled laboratory or other diagnostic tests in
35% and c) urgent evaluations in 4% (half of these or 2% due
to potential cardiovascular complaints).
Data collection. Trained nurses undertook chart abstrac-
tion of risk factors. These were considered to be present if
such condition was documented in the record before the
diagnosis of atrial flutter. Information was mostly collected
from typed physicians’ notes. Quality assurance methods to
ensure data integrity included reabstraction of every 10th
medical record, double data entry of a random sample of
10% of collected information as well as range and edit
checks on all collected data. All predetermined quality
assurance parameters were exceeded.
Statistical analysis. Incidence. The entire population of
MESA, including persons of all ages, was considered at risk
for developing atrial flutter. The number of verified incident
cases was divided by the total number of person-years of
observation of all MESA residents. Age- and gender-
specific rates are presented as well as age-adjusted rates,
calculated by using the 1990 U.S. census as standard.
Predisposing risk factors. To identify potential comor-
bidities associated with the development of atrial flutter, we
used an age- and gender-matched case-control design in
which atrial flutter was the outcome variable. Risk factors
potentially predisposing a subject to the development of
atrial flutter were chosen before data analysis. Selection of
the 13 putative etiologic variables employed in the analysis
was based on factors previously reported to predispose to
atrial fibrillation (22–25). Table 1 shows baseline clinical
diagnoses among cases and controls. For descriptive analy-
ses we compared distributions for categorical variables using
a chi-square test. We used Student t test to compare means
for continuous variables.
RESULTS
Incidence of atrial flutter in the general population.
Among 58,820 MESA residents, 181 new cases of atrial
flutter were diagnosed during the four years of ascertain-
ment (Table 2). Of these patients, 105 (58%) also had at
least one episode of atrial fibrillation. The overall incidence
of atrial flutter in the general population is 88/100,000.
“Atrial flutter only” was 37/100,000 person-years. Adjusted
for age, the incidence of atrial flutter in men (125/100,000,
95% confidence interval [CI] 102 to 149) was more than
twice that of women (59/100,000, 95% CI, 44 to 73). As
shown in Figure 1, the age-specific incidence of atrial flutter
increased with age in both males and females.
Clinical features at initial diagnosis. Baseline character-
istics of the 181 patients with atrial flutter and their
matched controls are shown in Table 1. For both groups the
Abbreviations and Acronyms
AA 5 antiarrhythmic
COPD 5 chronic obstructive pulmonary disease
DM 5 diabetes mellitus
ECG 5 electrocardiogram or electrocardiographic
HF 5 heart failure
ICD 5 International Classification of Diseases
MESA 5 Marshfield Epidemiologic Study Area
PSVT 5 paroxysmal supraventricular tachycardia









Heart failure (%) 22 8 0.001
Chronic pulmonary disease (%) 24 14 0.01
Diabetes mellitus (%) 16 10 0.07
Rheumatic heart disease (%) 2 1 0.18
Hyperlipidemia (%) 42 48 0.26
Myocardial infarction (%) 17 14 0.40
Hypertension (%) 47 52 0.60
Thyroid disease (%) 11 10 0.72
Mean age (yrs) 72 72 NS
Male gender (%) 62 62 NS
2243JACC Vol. 36, No. 7, 2000 Granada et al.
December 2000:2242–6 Predictors of Atrial Flutter
mean age was 72 6 12 (mean 6 standard deviation) years,
and 112 (62%) were men. The diagnosis was made by
multichannel ECG recording in 104 patients (57%) and by
12-lead ECG in 77 patients (43%). Type I atrial flutter was
diagnosed in 90% of the patients. In three cases (1.7%) there
were neither identifiable recent predisposing events nor
chronic preexisting comorbidities. These patients were la-
beled as having “lone atrial flutter.” The other 178 patients
(98.3%) had either definite documentation of a potentially
predisposing condition or proven structural heart disease. In
108 cases (59.7%) atrial flutter occurred for the first time
ever within 30 days of a likely predisposing event (such as
major surgical procedure, pneumonia, etc). Of these, 42
(23% of the total 181) had their initial episode within four
weeks of coronary artery bypass or valve replacement sur-
gery. In the remaining 70 cases (38.7%), atrial flutter was
associated with chronic comorbidities such as hypertension,
diabetes mellitus (DM), chronic obstructive pulmonary
disease (COPD), etc. At the time of initial diagnosis of
atrial flutter, none had undergone RFA, and five patients
(2.8%) were currently receiving AA drugs. Of these, four
were taking type IA drugs, and one was taking a class III
agent. None were on type IC AA agents.
Factors predisposing the development of atrial flutter.
Individuals with a history of heart failure (HF), (RR 3.5,
95% CI, 1.7 to 7.1) or COPD (RR 1.9, 95% CI l, 1.1 to 3.4)
were at increased risk of developing atrial flutter. Differences
among cases and controls regarding the other eight prese-
lected variables are shown in Table 3. Because of the
strength of association, the population-attributable risk for
developing atrial flutter was calculated. It was estimated that
15.8% and 11.6% atrial flutter cases in this cohort could be
attributed to HF and COPD, respectively. Antiarrhythmic
drugs did not predispose a subject to the development of
atrial flutter.
DISCUSSION
Our current knowledge of atrial flutter has been largely
derived from the published clinical experience of patients
referred to tertiary care centers (9–19). Recent technological
advances by these institutions have enhanced our under-
standing of the electrophysiologic mechanisms responsible
for its initiation and maintenance (2–8). Practical applica-
tion of this information has resulted in the widespread use
of catheter-based RFA as a safe and curative procedure in
these individuals. Despite these great technological achieve-
ments, little is known regarding the magnitude of this
problem or how to prevent atrial flutter in the population at
large (20). In fact, there are no previous reports on the
epidemiology of atrial flutter in the general population.
Framingham, the only population-based study that enrolled
patients with atrial flutter, used a working definition of
“atrial fibrillation” that included cases with either “atrial
fibrillation or atrial flutter on ECG.” Our data show that
atrial flutter is much more common than previously appre-
ciated.
Atrial flutter in the general population. Adjusted for the
U.S. population, the overall incidence of atrial flutter is
88/100,000 person-years. While in clinical practice atrial
flutter appears to be less common than PSVT, our data
show that in the general population, atrial flutter is diag-
nosed for the first time more than twice as often (26). If our
results were extrapolated to the entire U.S. population, we
estimate there would be 200,000 new cases of atrial flutter in
the U.S. annually. Approximately 80,000 of these would be
cases of “atrial flutter only.” Adjusted for age, the incidence
of atrial flutter in men (125/100,000) is more than 2.5 times
that of women (59/100,000). The age-specific incidence of
atrial flutter increases exponentially with age (Fig. 1) from
5/100,000 person-years in those ,50 years old to 587/
Figure 1. Incidence rates of atrial flutter by age and gender (100,000
person-years). Black squares 5 males; black circles 5 females.
Table 2. Incidence of Atrial Flutter in the General Population
Men Women Total
Person/Yr Cases Rate Person/Yr Cases Rate Person/Yr Cases Rate
0–49 yrs 84,915 6 0.07 82,250 2 0.02 167,165 8 0.05
50–59 yrs 8,715 15 1.72 8,643 4 0.46 17,358 19 1.09
60–69 yrs 7,223 29 4.02 7,982 20 2.51 15,204 49 3.22
70–79 yrs 5,943 36 6.06 7,918 21 2.65 13,862 57 4.11
801 yrs 2,837 26 9.16 5,337 22 4.12 8,174 48 5.87
Total 109,634 112 1.02 112,129 69 0.62 221,763 181 0.82
Total-age adjusted* 1.25 0.59 0.88
(95% CI) (1.02, 1.49) (0.44, 0.73) (0.75, 1.01)
*Age-adjusted using the 1990 U.S. total white population census.
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100,000 person-year among individuals $80 years, an
increase of more than a hundred fold in the elderly. At the
time of initial diagnosis, nearly all new cases (173 of 181,
96%) were .50 years of age. The incidence rate of atrial
flutter in this large subset of our patients is an astonishing
317/100,000 person-years, a figure that approaches that
reported for atrial fibrillation (27).
Clinical risk factors associated with atrial flutter. In
addition to advancing age and male gender, at highest risk
of developing atrial flutter were MESA residents with HF
and COPD. A weaker association was also noted for those
with DM (p 5 0.07). The risk of developing atrial flutter
increased 3.5 times in HF (p , 0.001) and 1.9 times (p ,
0.001) in those with COPD. Sixteen percent of atrial flutter
cases were attributable to HF and 12% to COPD. While we
may have found previously unidentified risk factors for
developing atrial flutter, only a small portion of the new
cases can be explained by these predisposing conditions
alone. The contribution of HF, COPD, DM and other
conditions may have been underestimated due to potentially
incomplete ascertainment of mild cases.
At the time of the initial diagnosis, only four of 181
(2.2%) patients were taking AA drugs. It is unlikely,
therefore, that the conversion of atrial fibrillation into atrial
flutter is a likely etiology of atrial flutter in the general
population.
We have recently reported a kindred study with an
autosomal dominant dilated cardiomyopathy in which atrial
flutter is an early expression of the disease (28). Their
genetically based cardiomyopathy was caused by a missense
mutation in the rod domain of a lamin gene. Since one of
the affected families was from MESA, we evaluated whether
familial clustering on that basis was contributing to our
findings. A comparison of the surnames of all 181 atrial
flutter cases in this epidemiologic study with the 13 last
names in the two affected families failed to identify any
evidence among study patients. These observations do not
exclude a potentially genetic contribution to the develop-
ment of atrial flutter.
Further research is needed to determine whether aggres-
sive efforts targeting earlier identification of individuals at
risk as well as primary prevention and innovative treatments
of the treatable predisposing conditions can impact the
occurrence of atrial flutter and its associated complications.
Study limitations. We minimized selection bias by iden-
tifying practically all cases occurring in the entire population
of a defined region. Although ICD-9-CM coding of med-
ical conditions may not be completely accurate, we used a
large set of codes in an attempt to identify all cases. It is
unlikely that we missed many, if any, incident cases of
clinically significant atrial flutter. Given its intermittent and
often asymptomatic nature and the existing technological
limitations, complete ascertainment of atrial flutter in any
population would require life long continuous monitoring of
all individuals in the area, a study not likely to ever be
feasible or ethical. To identify risk factors for developing
atrial flutter, we used an age- and gender-matched case-
control design in which atrial flutter was the outcome
variable. Unlike studies of volunteer cohorts screened over
time, MESA represents an unselected sample representative
of an entire population. The MESA population is predom-
inantly white and rural. Though we are not aware of studies
establishing racial, ethnic or residential predisposition to
atrial flutter, our results should be used cautiously to project
to other population groups.
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